• Follow
  • Follow
  • Follow
  • Follow
U

Search



Shop

w

News

w

Blog

DONATE
Team Jack Foundation
  • About Us
    • Our Mission
    • Jack Hoffman
    • Board & Staff
    • Financials
  • Our Impact
    • Scientific Advisory Board
    • Sponsored Grants
    • Research Articles
  • Brain Cancer
    • What is Brain Cancer?
      • What is DIPG?
    • Brain Cancer Facts
    • Cancer Awareness Months
      • Brain Tumor Awareness Month
    • Family Resources
  • Events
  • Get Involved
    • Fundraise
      • Host an Event
      • Run For Team Jack
      • Birthday Fundraiser
    • Give
    • Our Sponsors
    • Volunteer
  • Heroes
  • Donate
  • Shop
  • Blog
  • News
Select Page

Get Involved

Clinical Trial Finder

Search Results

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Study Purpose

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Male or female subjects ≥18 years of age. 2. Documented carcinoid syndrome requiring medical therapy. 1. Not currently treated with somatostatin receptor ligands agonists for at least 12 weeks prior to screening and actively symptomatic. This can include treatment-naïve subjects. 2. Subjects currently treated with lanreotide, octreotide long acting release, or short acting octreotide (subcutaneous or oral) who are currently symptomatically controlled. 3. Evaluable documentation of locally advanced or metastatic histopathologically confirmed well-differentiated neuroendocrine tumor (NET). 4. No significant disease progression as assessed by the Investigator within the last 6 months before initiation of study drug dosing.

Exclusion Criteria:

1. Diarrhea attributed to any condition(s) other than carcinoid syndrome. 2. Uncontrolled/severe diarrhea associated with significant volume contraction, dehydration, or hypotension. 3. Requires second line treatments (eg, telotristat) for control of carcinoid syndrome symptoms. 4. Treatment with specific NET tumor therapy <4 weeks before Screening (such as everolimus or sunitinib) or hepatic embolization, radiotherapy, peptide receptor radionuclide therapy (PRRT), and/or tumor debulking <12 weeks before Screening. 5. History of another primary malignancy <3 years prior to the date of first dose, except for adequately treated basal or squamous cell carcinoma of the skin, cancer of the breast or cervix in situ, previously treated or concurrent malignancy determined to be clinically stable and not requiring treatment. 6. Diabetes mellitus treated with insulin for less than 6 weeks prior to the study entry

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05361668
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Crinetics Pharmaceuticals Inc.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries Argentina, Brazil, Canada, Mexico, Peru, Poland, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas
Arms & Interventions

Arms

Experimental: 40 mg Paltusotine

Experimental: 80 mg Paltusotine

Interventions

Drug: - Randomized: 40 mg Paltusotine

Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)

Drug: - Randomized: 80 mg Paltusotine

Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Crinetics Study Site, Los Angeles, California

Status

Address

Crinetics Study Site

Los Angeles, California, 90048

Crinetics Study Site, Los Angeles, California

Status

Address

Crinetics Study Site

Los Angeles, California, 90095

Crinetics Study Site, Newport Beach, California

Status

Address

Crinetics Study Site

Newport Beach, California, 92663

Crinetics Study Site, Stanford, California

Status

Address

Crinetics Study Site

Stanford, California, 94305

Crinetics Study Site, Miami, Florida

Status

Address

Crinetics Study Site

Miami, Florida, 33136

Crinetics Study Site, Iowa City, Iowa

Status

Address

Crinetics Study Site

Iowa City, Iowa, 52242

Crinetics Study Site, Lexington, Kentucky

Status

Address

Crinetics Study Site

Lexington, Kentucky, 40506

Crinetics Study Site, New Orleans, Louisiana

Status

Address

Crinetics Study Site

New Orleans, Louisiana, 70112

Crinetics Study Site, Boston, Massachusetts

Status

Address

Crinetics Study Site

Boston, Massachusetts, 02118

Crinetics Study Site, Rochester, Minnesota

Status

Address

Crinetics Study Site

Rochester, Minnesota, 55905

Crinetics Study Site, New York, New York

Status

Address

Crinetics Study Site

New York, New York, 10029

Crinetics Study Site, Stony Brook, New York

Status

Address

Crinetics Study Site

Stony Brook, New York, 11794

Crinetics Study Site, Cleveland, Ohio

Status

Address

Crinetics Study Site

Cleveland, Ohio, 44106

Crinetics Study Site, Columbus, Ohio

Status

Address

Crinetics Study Site

Columbus, Ohio, 43210

Crinetics Study Site, Houston, Texas

Status

Address

Crinetics Study Site

Houston, Texas, 77030

International Sites

Crinetics Study Site, Caba, Buenos Aires, Argentina

Status

Address

Crinetics Study Site

Caba, Buenos Aires, C1180 AAX

Crinetics Study Site, Caba, Buenos Aires, Argentina

Status

Address

Crinetics Study Site

Caba, Buenos Aires, C1264AAA

Crinetics Study Site, Caba, Buenos Aires, Argentina

Status

Address

Crinetics Study Site

Caba, Buenos Aires, C1426ANZ

Crinetics Study Site, Caba, Argentina

Status

Address

Crinetics Study Site

Caba, , C1017AAS

Crinetics Study Site, Caba, Argentina

Status

Address

Crinetics Study Site

Caba, , C1425BGH

Crinetics Study Site, Fortaleza, Ceará, Brazil

Status

Address

Crinetics Study Site

Fortaleza, Ceará, 60430-275

Crinetics Study Site, Criciúma, Santa Catarina, Brazil

Status

Address

Crinetics Study Site

Criciúma, Santa Catarina, 88811508

Crinetics Study Site, Rio De Janeiro, Brazil

Status

Address

Crinetics Study Site

Rio De Janeiro, , 20231-092

Crinetics Study Site, Rio De Janeiro, Brazil

Status

Address

Crinetics Study Site

Rio De Janeiro, , 22061-080

Crinetics Study Site, Rio De Janeiro, Brazil

Status

Address

Crinetics Study Site

Rio De Janeiro, , 22281-100

Crinetics Study Site, São Paulo, Brazil

Status

Address

Crinetics Study Site

São Paulo, , 01509-010

Crinetics Study Site, Toronto, Canada

Status

Address

Crinetics Study Site

Toronto, , M4N 3M5

Crinetics Study Site, Mexico City, Cuauhtemoc, Mexico

Status

Address

Crinetics Study Site

Mexico City, Cuauhtemoc, 06100

Crinetics Study Site, Santiago De Querétaro, Querétaro, Mexico

Status

Address

Crinetics Study Site

Santiago De Querétaro, Querétaro, 76000

Crinetics Study Site, Santiago De Querétaro, Querétaro, Mexico

Status

Address

Crinetics Study Site

Santiago De Querétaro, Querétaro, 76070

Crinetics Study Site Peru #1, Lima, Peru

Status

Address

Crinetics Study Site Peru #1

Lima, , 15036

Crinetics Study Site Peru #2, Lima, Peru

Status

Address

Crinetics Study Site Peru #2

Lima, , 15036

Crinetics Study Site, Katowice, Poland

Status

Address

Crinetics Study Site

Katowice, , 40-514

Crinetics Study Site, Warszawa, Poland

Status

Address

Crinetics Study Site

Warszawa, , 02-351

Crinetics Study Site, Wrocław, Poland

Status

Address

Crinetics Study Site

Wrocław, , 53-413

Resources

  • Patient and Caregiver Survey
  • Clinical Trial Endpoints
  • Research Resources
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Make an impact through your inbox

News, upcoming events and research updates delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.
MAKE AN IMPACT

Donate today to help the Team Jack Foundation fund research and fight pediatric brain cancer.

Make a Donation
  • About Us
  • Our Mission
  • Jack Hoffman
  • Board & Staff
  • Fund Allocation
  • Financials
  • Our Impact
  • Scientific Advisory Board
  • Sponsored Grants
  • Research Articles
  • Brain Cancer
  • Family Resources
  • Get Involved
  • Fundraise
  • Give
  • Events
  • Our Sponsors
  • Volunteer
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
seal of transparency badge - 2019 Gold
combined health agencies drive member charity badge
Share Omaha member badge
© 2021 Team Jack Foundation. PO Box 607, Atkinson, NE, 68713. All Rights Reserved. Team Jack Foundation, Inc. is exempt from federal income tax under section 501(c)3, ID Number 46-2301134, of the internal revenue code. All contributions to the Foundation are tax deductible. Privacy Policy • Contact